1Appell RA, Norton PA, Kawabe K. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: apoolad analysis [J]. Urology, 1997, 50(6A) : 90-99.
2Botteghi C, Corrias T, Marchetti M, et al. A new efficient route to tolterodine [J]. Org Process Res Dev, 2002, 6 (4) : 379-383.
3Erik F. Process for preparation of 3-(2-hydroxy-5- substitutedphenyl)-N-alkyl-3-phenylpropylamines: WO, 2007147547 [P]. 2007-12-27. (CA2007, 148: 100381)
5Ahman JB, Dillon BR, Pettman AJ. Process for the production of benzopyran-2-ol derivatives: WO, 2007138440 [P]. 2007-12-06. (CA 2007, 148: 33629)
6De Castro KA, Ko J, Park D. Reduction of ethyl benzoylacetate and selective protection of 2- (3-hydroxy-1- phenylpropyl) -4-methylphenol: A new and facile synthesis of tolterodine [J]. Org Process Res Dev, 2007, 11 (5) : 918-921.
7Joensson NA, Sparf BA, Mikiver L, et al. 3,3-Diphenylpropylamines and pharmaceutical compositions thereof: US, 5382600 [P]. 1995-01-17. (CA 1989, 112: 55211)
8Gage JR, Cabaj JE. Process to prepare tolterodine: WO, 1998029402 [P]. 1998-07-09. (CA 1998, 129: 95317)
9Flores SP, Avila Quevedo SA. Method for the preparation of (R)-tolterodine tartrate: WO, 2008020332 [P]. 2008-02-21. (CA 2008, 148: 284897)
